The European Glaucoma Prevention Study (EGPS) showed that treatment of ocular hypertension with dorzolamide treatment alone did not significantly reduce intraocular pressure or progression to primary open angle glaucoma when compared to treatment with placebo. This result can be explained by the study design, regression to the mean at 6 months in both arms of the study and selective loss to follow-up of participants with higher intraocular pressures. IOP intraocular pressure, POAG primary open angle glaucoma and CI confidence interval.
Change history
03 August 2021
A Correction to this paper has been published: https://doi.org/10.1038/s41433-021-01713-9
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The original online version of this article was revised: Unfortunately, the middle initial was missing by author’s name Rashmi G. Mathew.
Rights and permissions
About this article
Cite this article
Han, J.E., Mathew, R.G. & Henein, C. Infographic of the European Glaucoma Prevention Study (EGPS). Eye 36, 682 (2022). https://doi.org/10.1038/s41433-021-01420-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41433-021-01420-5
